NorthStar Medical Radioisotopes has appointed a new senior vice president and chief operating officer (COO), a newly created position with the company.
Stephen Merrick has 24 years of experience in the biotechnology, pharmaceutical, and life sciences sector, having held multiple executive positions with global companies, NorthStar said. He will oversee day-to-day operations at NorthStar, including engineering, production, and customer service, as the company advances toward U.S. Food and Drug Administration (FDA) clearance of its RadioGenix isotope separation system and commercialization of the two new processes it is developing for producing the isotope molybdenum-99 (Mo-99).
Merrick comes to NorthStar from Baxter International, where he was vice president of international marketing for the company's Hospital Products business. Prior to that, he was a senior vice president and president of international commercial operations for Mallinckrodt Pharmaceuticals, and he worked for Bristol-Myers Squibb for 17 years. He began his career with Eli Lilly.
